Nathan A Pennell

List of Publications by Citations

142 papers	10,676 citations	33 h-index	103 g-index
160 ext. papers	14,097 ext. citations	6.6 avg, IF	7.83 L-index

#	Paper	IF	Citations
142	Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **2014**, 511, 543-50	50.4	3310
141	Reactive microgliosis. *Progress in Neurobiology*, **1999**, 57, 563-81	10.9	986
140	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet, The*, **2020**, 395, 1907-1918	60	880
139	Pan-cancer analysis of whole genomes. *Nature*, **2020**, 578, 82-93	50.4	840
138	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nature Medicine*, **2008**, 14, 822-7	50.5	835
137	Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 4417-24	2.2	350
136	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. *Cancer Discovery*, **2018**, 8, 1548-1565	24.4	258
135	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. *Chest*, **2017**, 152, 271-281	5.3	249
134	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 813-824	59.2	194
133	A phase II study of gefitinib in patients with advanced thyroid cancer. *Thyroid*, **2008**, 18, 317-23	6.2	162
132	Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. *Journal of Neuroimmunology*, **1998**, 86, 1-12	3.5	148
131	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). *Journal of Thoracic Oncology*, **2018**, 13, 1393-1399	8.9	118
130	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 230-241	7.3	112
129	Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 531-542	7.1	107
128	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 1547-52	11.5	96
127	Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. *Journal of Thoracic Oncology*, **2018**, 13, 1771-1775	8.9	96
126	A genetic basis for the variation in the vulnerability of cancer to DNA damage. *Nature Communications*, **2016**, 7, 11428	17.4	95

125	ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. *Journal of Molecular Diagnostics*, **2013**, 15, 341-6	5.1	94
124	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. *Seminars in Oncology*, **2015**, 42 Suppl 2, S3-10	5.5	90
123	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2019**, 37, 97-104	2.2	83
122	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discovery*, **2020**, 10, 1514-1527	24.4	80
121	Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. *Oncologist*, **2009**, 14, 399-411	5.7	76
120	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 1341-1367	2.2	75
119	Time to initial cancer treatment in the United States and association with survival over time: An observational study. *PLoS ONE*, **2019**, 14, e0213209	3.7	71
118	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. *Blood Advances*, **2020**, 4, 5966-5975	7.8	66
117	Prospective Clinical Study of Precision Oncology in Solid Tumors. *Journal of the National Cancer Institute*, **2015**, 108,	9.7	56
116	ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. *Journal of Thoracic Oncology*, **2014**, 9, 464-8	8.9	51
115	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2020**, 38, 1081	2.2	48
114	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncology*, **2021**,	13.4	47
113	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). *Lung Cancer*, **2014**, 86, 158-63	5.9	41
112	XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. *Journal of Thoracic Oncology*, **2012**, 7, 219-26	8.9	41
111	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Clinical Lung Cancer*, **2018**, 19, e335-e348	4.9	39
110	RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. *Journal of Thoracic Oncology*, **2014**, 9, 1714-9	8.9	33
109	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. *JCO Precision Oncology*, **2017**, 1, 1-15	3.6	31
108	Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. *PLoS ONE*, **2018**, 13, e0197743	3.7	31

107	Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.. *Journal of Clinical Oncology*, **2018**, 36, 9031-9031	2.2	29
106	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. *Journal of Clinical Oncology*, **2019**, 37, 2360-2367	2.2	28
105	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. *Lung Cancer*, **2017**, 112, 181-187	5.9	28
104	Colonization of Neural Allografts by Host Microglial Cells: Relationship to Graft Neovascularization. *Cell Transplantation*, **1997**, 6, 221-230	4	28
103	Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. *Investigational New Drugs*, **2014**, 32, 362-8	4.3	25
102	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. *Journal of Clinical Oncology*, **2014**, 32, 7514-7514	2.2	25
101	High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2014**, 9, 646-53	8.9	24
100	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. *Journal of Thoracic Disease*, **2018**, 10, 3909-3921	2.6	24
99	Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. *Practical Radiation Oncology*, **2013**, 3, 301-6	2.8	21
98	Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.. *JCO Precision Oncology*, **2019**, 3, 1-9	3.6	21
97	Lectin staining of sheep microglia. *Histochemistry*, **1994**, 102, 483-6		20
96	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. *Oncologist*, **2015**, 20, 1298-303	5.7	18
95	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. *Seminars in Hematology*, **2017**, 54, 198-204	4	18
94	InternsQwork hours. *New England Journal of Medicine*, **2005**, 352, 726-8; author reply 726-8	59.2	18
93	Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2009**, 4, 1156-62	8.9	17
92	Colonization of neural allografts by host microglial cells: relationship to graft neovascularization. *Cell Transplantation*, **1997**, 6, 221-30	4	17
91	Impact of the COVID-19 Pandemic on Healthcare WorkersQRisk of Infection and Outcomes in a Large, Integrated Health System. *Journal of General Internal Medicine*, **2020**, 35, 3293-3301	4	17
90	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. *Lung Cancer*, **2018**, 123, 14-21	5.9	16

89	Clinical Cancer Advances 2021: ASCO® Report on Progress Against Cancer. *Journal of Clinical Oncology*, **2021**, 39, 1165-1184	2.2	16
88	Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. *Clinical Lung Cancer*, **2011**, 12, 350-9	4.9	14
87	Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 8504-8504	2.2	14
86	Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. *Oncologist*, **2020**, 25, 562-e1012	5.7	13
85	Characterization of myomodulin-related peptides from the pulmonate snail Helix aspersa. *Peptides*, **1997**, 18, 1099-106	3.8	13
84	Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 822-829	15.4	13
83	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell*, **2020**, 38, 761-766	24.3	12
82	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. *Lung Cancer*, **2017**, 111, 108-115	5.9	11
81	Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. *Neuro-Oncology*, **2020**, 22, 267-277	1	11
80	Tracing of fluoro-gold prelabeled microglia injected into the adult rat brain **1998**, 23, 84-88		11
79	Biofeedback Assisted Stress Management in Patients with Lung Cancer: A Feasibility Study. *Applied Psychophysiology Biofeedback*, **2015**, 40, 201-8	3.4	10
78	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 144-154	7.1	10
77	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. *Cancer Treatment and Research Communications*, **2019**, 19, 100126	2	9
76	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. *Nature Communications*, **2019**, 10, 5143	17.4	9
75	Selection of chemotherapy for patients with advanced non-small cell lung cancer. *Cleveland Clinic Journal of Medicine*, **2012**, 79 Electronic Suppl 1, eS46-50	2.8	9
74	Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. *JCO Precision Oncology*, **2021**, 5,	3.6	9
73	Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors.. *Journal of Clinical Oncology*, **2017**, 35, 6557-6557	2.2	8
72	Lung cancer treatment outcomes in recipients of lung transplant. *Translational Lung Cancer Research*, **2015**, 4, 784-91	4.4	8

71	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. *Translational Lung Cancer Research*, **2013**, 2, 251-5	4.4	8
70	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). *Annals of Oncology*, **2020**, 31, S1202-S1203	19.3	7
69	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 144-154	7.1	7
68	Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. *European Journal of Cancer*, **2021**, 148, 146-158	7.5	7
67	Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 11603-11603	2.2	6
66	The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2522-2532	15.4	6
65	Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. *Cancer*, **2020**, 126, 1060-1067	6.4	5
64	Best Practices in Treatment Selection for Patients With Advanced NSCLC. *Cancer Control*, **2016**, 23, 2-14	2.2	5
63	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. *JAMA Oncology*, **2016**, 2, 569-570	13.4	5
62	Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. *Annals of Translational Medicine*, **2017**, 5, 378	3.2	5
61	Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute. *Journal of Oncology Practice*, **2016**, 12, e101-7	3.1	5
60	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. *Oncologist*, **2019**, 24, 4-8	5.7	5
59	"My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?" Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 696-707	7.1	5
58	Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. **2022**, 10,		5
57	Patterns of Recurrence and Overall Survival in Incidental Lung Cancer in Explanted Lungs. *Annals of Thoracic Surgery*, **2019**, 107, 891-896	2.7	4
56	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. *Oncologist*, **2020**, 25, 921-924	5.7	4
55	Investigational agents in the management of non-small cell lung cancer. *Current Oncology Reports*, **2009**, 11, 275-84	6.3	4
54	Prospective clinical study of precision oncology in solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, 6585-6585	2.2	4

53	A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States.. *Journal of Clinical Oncology*, **2020**, 38, 9529-9529	2.2	4
52	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. *JAMA Network Open*, **2022**, 5, e224304	10.4	4
51	Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?. *Current Treatment Options in Oncology*, **2012**, 13, 478-90	5.4	3
50	Hereditary implications of somatic tumor testing.. *Journal of Clinical Oncology*, **2015**, 33, 1523-1523	2.2	3
49	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9079-9079	2.2	3
48	Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.. *Journal of Clinical Oncology*, **2017**, 35, 11547-11547	2.2	3
47	A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS2598-TPS2598	2.2	3
46	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience.. *JCO Precision Oncology*, **2018**, 2, 1-11	3.6	3
45	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. *Translational Lung Cancer Research*, **2021**, 10, 3071-3078	4.4	3
44	Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib. *Journal of Thoracic Oncology*, **2012**, 7, 1200-1	8.9	2
43	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. *Biomarkers in Medicine* , **2007**, 1, 203-7	2.3	2
42	Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. *Blood*, **2020**, 136, 7-8	2.2	2
41	Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study. *Blood*, **2019**, 134, 3651-3651	2.2	2
40	Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 11582-11582	2.2	2
39	Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer. *Clinical Lung Cancer*, **2011**, 12, 94-9	4.9	1
38	Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib. *Journal of Oncology Practice*, **2012**, 8, 34s-7s	3.1	1
37	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. *Blood*, **2020**, 136, 56-58	2.2	1
36	Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).. *Journal of Clinical Oncology*, **2015**, 33, 6609-6609	2.2	1

35	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. *Journal of Clinical Oncology*, **2016**, 34, 9059-9059	2.2	1
34	Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress. *Translational Lung Cancer Research*, **2012**, 1, 149-51	4.4	1
33	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.. *Clinical Lung Cancer*, **2021**,	4.9	1
32	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. *JAMA Network Open*, **2022**, 5, e2142046	10.4	1
31	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. *Reviews on Recent Clinical Trials*, **2017**, 12, 51-58	1.2	1
30	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. *Journal of Clinical Oncology*, **2014**, 32, 191-191	2.2	1
29	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. *Oncologist*, **2021**, 26, 523-532	5.7	1
28	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. *Scientific Reports*, **2021**, 11, 7490	4.9	1
27	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. *Lung Cancer*, **2018**, 126, 48-54	5.9	1
26	Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.. *Journal of Clinical Oncology*, **2017**, 35, e20647-e20647	2.2	0
25	Phase II study of stereotactic radiosurgery or other local ablation followed by erlotinib for patients with EGFR mutation who have previously progressed on an EGFR tyrosine kinase inhibitor (TKI).. *Journal of Clinical Oncology*, **2017**, 35, e20623-e20623	2.2	0
24	Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. *Oncologist*, **2020**, 25, 364-365	5.7	0
23	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. *Scientific Reports*, **2021**, 11, 18174	4.9	0
22	The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator.. *JCO Oncology Practice*, **2022**, OP2100763	2.3	0
21	Superior vena cava syndrome in lung cancer. *Lung Cancer Management*, **2012**, 1, 309-315	2.6	
20	Patients as real time teachers. *Journal of Cancer Education*, **2007**, 22, 131-3	1.8	
19	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. *Blood*, **2020**, 136, 41-42	2.2	
18	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. *Translational Lung Cancer Research*, **2013**, 2, E1-3	4.4	

17	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. *Blood*, **2021**, 138, 3223-3223	2.2
16	PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non-small-cell lung cancer (ES-NSCLC).. *Journal of Clinical Oncology*, **2018**, 36, 12059-12059	2.2
15	Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.. *Journal of Clinical Oncology*, **2018**, 36, e18710-e18710	2.2
14	Identifying delays in care for patients with NSCLC using value-stream mapping.. *Journal of Clinical Oncology*, **2018**, 36, 136-136	2.2
13	Circulating tumor cells enrichment and characterization in ALK-translocation positive lung cancer.. *Journal of Clinical Oncology*, **2014**, 32, e19025-e19025	2.2
12	Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.. *Journal of Clinical Oncology*, **2014**, 32, e12515-e12515	2.2
11	Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.. *Journal of Clinical Oncology*, **2015**, 33, 6565-6565	2.2
10	Patient-centered outcomes with post-approval nivolumab in metastatic NSCLC at the Cleveland Clinic Taussig Cancer Institute (TCI).. *Journal of Clinical Oncology*, **2016**, 34, 29-29	2.2
9	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. *Journal of Clinical Oncology*, **2016**, 34, e14073-e14073	2.2
8	Preoperative neutrophil lymphocyte ratio as a predictor of outcomes in patients with early stage non-small cell lung cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23069-e23069	2.2
7	The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology* , **2016**, 34, e21688-e21688	2.2
6	Precision oncology experience at a tertiary care center.. *Journal of Clinical Oncology*, **2017**, 35, e18118-e18118	2.2
5	Association of delays in time to surgery for resectable stage IIIA non-small cell lung cancer with survival.. *Journal of Clinical Oncology*, **2017**, 35, e20056-e20056	2.2
4	Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer. *JAMA Oncology*, **2021**, 7, 679-680	13.4
3	Fast-Growing Plasmacytoma. *American Journal of the Medical Sciences*, **2016**, 351, 308	2.2
2	An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. *Oncologist*, **2019**, 24, 457-e126	5.7
1	Response to: Correspondence on "Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab" by Zheng et al **2022**, 10, e005086	